Pulmonx Corporation
HealthcareNASDAQ:LUNG · NASDAQ Global Select
-$0.05 today
Vol 0.23M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-99.8%
avg -34.1%
ROIC
-48.5%
avg -57.1%
ROA
-41.8%
avg -42.0%
Analysis
ROA is currently the strongest return metric at -41.8% versus its period average of -42.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Geoffrey Beran Rose | Chief Commercial Officer | $632,293.00 | — | 52 | $465,734.00 | 1.10% |
David A. Lehman | General Counsel & Secretary | $516,643.00 | — | 65 | $244,806.00 | 0.58% |
Glendon E. French | Chief Executive Officer, President & Director | $319,520.00 | — | 64 | $1.47M | 3.49% |
Derrick Sung | Chief Financial Officer & Chief Operating Officer | $283,391.00 | — | 53 | $1.34M | 3.16% |
Narinder S. Shargill | Senior Vice President of Global Medical & Clinical Affairs | — | — | 71 | $363,497.00 | 0.86% |
Jérôme Erath | Senior Vice President & GM of International | — | — | — | — | — |
John McKune | VP of Finance & Corporate Controller | — | — | 50 | $76,210.00 | 0.18% |
Sri Radhakrishnan | Chief Science & Technology Officer | — | — | — | $177,395.00 | 0.42% |
Lisa Paul | Chief People Officer | — | — | 62 | — | — |
Srikanth Radhakrishnan | Chief Science & Technology Officer | — | — | 53 | $177,395.00 | 0.42% |
Marcee Maroney | Vice President of Marketing | — | — | 56 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
38
$281,047.19
Net Sentiment
$281,047.19
Net selling
Most Active
Rose Geoffrey Beran
12 transactions
1–10 of 38
Analysis
Insiders reported 0 buys worth $0.00 and 38 sells worth $281,047.19 over the last 12 months. That adds up to net selling of $281,047.19. Rose Geoffrey Beran was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +18.1% | +12.9% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.1% over three years. Forward estimates point to Revenue at +12.9% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Edap Tms S.a.
EDAP
$178.23M
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.73M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Hyperfine, Inc.
NASDAQ:HYPR
$114.53M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
TELA Bio, Inc.
TELA
$38.50M
Who manages LUNG?
Pulmonx Corporation (LUNG) lists 11 active executives. The top listed executive is Geoffrey Beran Rose, Chief Commercial Officer.
Are LUNG insiders buying or selling?
Recent insider activity shows net buying of $5.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.